Table 1.
Small‐molecule chemical drugs able to inhibit NLRP3 activation in animal models of digestive diseases.
| Drugs | Molecular mechanisms | Experimental model | Reference | Clinical trials |
|---|---|---|---|---|
| MCC950 | Modifying the active conformation of NLRP3 Affecting the hydrolysis of ATP |
Pancreatic cancer Liver injury and fibrosis UC |
(80, 160–162) | null |
| OLT1177 | Preventing NLRP3 aggregation with ASC | DSS-induced colitis | (163) | null |
| WT161 | HDAC6 inhibitor | IBD | (164) | null |
| Blocking NLRP3 inflammasome activation, disrupting ASC speck formation, and decreasing the expression of NLRP3 | ||||
| Withaferin A (WA) | Inhibition of NF-κB signaling pathway | Pancreatitis | (165) | null |
| F240B | Induction of SIRT1-dependent autophagy | Peritonitis | (166) | null |
| Inhibiting ASC oligomerization and pro-IL-1β expression | ||||
| GL-V9 | Trigger of autophagy to degrade NLRP3 inflammasome | Liver cancer | (167–169) | null |
| Colorectal cancer | ||||
| Iguratimod (T-614) | Inhibition of NLRP3 inflammasome activation | SAP | (170) | null |
| Methane | Inhibition of TLR4/NF-κB/NLRP3 signaling pathway | Cholestatic liver injury | (171) | null |
| Angiotensin- (1–7) | Inhibition of Ang II-mediated ROS | HF | (172) | null |